Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › TLX

Telix Pharmaceuticals

TLX Lead: Approved 1 Biotech Distilled article ↓ 25 filings & releases ↓ Cash $142M (Dec 31, 2025) ↓ 1 verdict ↓ 1 timing quote ↓
Oncology ProteinSmall Molecule

Market cap $3.27B 339.8M shares (vendor count, Nov 7, 2026) × $9.63 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-02-20

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. ITM acquisition strategic reviewDec 1, 2026ITM acquisition strategic review, Dec 1, 2026, notable
  2. BiPASS topline1H 2027BiPASS topline, 1H 2027, thesis-defining
  3. TLX597-Tx PSMA topline1H 2027TLX597-Tx PSMA topline, 1H 2027, material
  4. Illuccix China/Japan; Pixlumi EU; ITM2027Illuccix China/Japan; Pixlumi EU; ITM, 2027, notable
  5. Telix corporate guidance updateFeb 2027Telix corporate guidance update, Feb 2027, routine
  6. CONVERGE-01 ²²⁵Ac-rosopatamab Ph3 startPhase 3 planned mid-2027CONVERGE-01 ²²⁵Ac-rosopatamab Ph3 start, Phase 3 planned mid-2027, routine
  7. ITM-11 FDA approvalDec 31, 2027ITM-11 FDA approval, Dec 31, 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (25 active programs)

Technology platforms

AlFluor · University Hospital Ghent / Ghent University

Novel PET radiochemistry solution based on fluorine-18 (18F)-aluminum fluoride (AlF) for product lifecycle management; focus on prostate cancer imaging with [18F]AlF-PSMA-11

Targets: PSMA

RADmAb

Proprietary antibody engineering technology platform that modulates pharmacokinetics of full-length antibodies to clear faster from blood while maintaining target specificity and tumor localization; designed to optimize therapeutic window for radiopharmaceutical antibody-drug conjugates (rADCs) in oncology

AlFluor · University Hospital Ghent

Novel PET radiochemistry platform based on 18F-aluminum fluoride (AlF) enabling flexible radiolabeling of PSMA and other ligands (neuroendocrine tumors, FAP) with either AlF or 68Ga; supports centralized cyclotron and distributed kit-based production for prostate cancer and other oncology indications

Targets: PSMA

AlFluor

AlFluor — radiopharmaceutical precision medicine platform associated with TLX593-Px; disease focus not specified in document

Discontinued (1)

Capital (as filed)

Cash
$142M cash and cash equivalents · Dec 31, 2025 (20-F)
Operating cash flow
−$4.3M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$252M cash per the deep dive of Oct 20, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Telix Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-21 Watch Telix Pharmaceuticals (TLX) - Scientific Deep Dive for Illuccix, Gozellix, TLX591-Tx and Pipeline Products Telix's profitable gallium imaging franchise lacks durable patent protection and is funding an unproven therapeutics strategy via dilutive M&A; wait for the ITM vote, pricing data against new competition, and BiPASS readout before owning it.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 20, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)